Search | Clinical Trials Finder

Conditions: Kidney Transplantation
Interventions: Mycophenolate mofetil, Cyclosporine, Tacrolimus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 57
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more

Conditions: Meibomian Gland Dysfunction (MGD)
Interventions: Vevye(Cyclosporine 0.1% Ophthalmic Solution); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Cyclophosphamide, Cetuximab; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Surgery, Immune System and Related Disorders, Preoperative Care, Gastrointestinal Disease, Urological Disease, Gynecologic Disease, Thoracic Diseases
Interventions: Physical Prehabilitation, Stress Reduction Prehabilitation, Cognitive Prehabilitation, Nutrition Prehabilitation; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Atherosclerosis, Kidney Failure
Interventions: tacrolimus, mycophenolate mofetil, prednisone, sirolimus; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions: therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Kidney Transplantation
Interventions: cyclosporine, Prograf (Tacrolimus); Drug
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Avatrombopag, Standard of care; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Watertown, South Dakota

Conditions: Dry Eye
Interventions: Voclosporin Ophthalmic Solution, Restasis®; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 7
States / cities: Garden Grove, California • Mission Hills, California • Rancho Cordova, California + 4 more

Conditions: Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
Interventions: Gamunex-C; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions: Cyclosporine, Methylprednisolone and Prednisone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Child Sexual Abuse
Interventions: Healthy Relationships Project; Behavioral
Lead sponsor: Northeastern University; Other
Eligibility: 3 Years to 11 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Interventions: T-cell replete PBPC allograft, Methotrexate, Cyclosporine, G-CSF; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Renal Transplantation
Interventions: Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 53
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more

Conditions: KidneyTransplant Recipients, Simultaneous Kidney/Pancreas Recipients, Kidney Transplant Donor
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide, Cyclosporine, Doxorubicin hydrochloride, Etoposide, Fludarabine phosphate, Prednisone, Vincristine Sulfate, Methotrexate, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor); Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, tacrolimus, laboratory biomarker analysis, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation; Biological · Drug · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more

Conditions: Corneal Transplantation, Corneal Graft Rejection
Interventions: LX201, Placebo; Drug · Other
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 24
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more

Conditions: Dry Eye
Interventions: Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free; Drug
Lead sponsor: Research Insight LLC; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Hemet, California • Laguna Hills, California • Brecksville, Ohio

Conditions: Cardiac Surgical Procedures
Interventions: cyclosporine, saline solution; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Graft Rejection, Kidney Failure
Interventions: cyclosporine or tacrolimus, sirolimus; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 8
States / cities: Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more

Conditions: Acute Kidney Injury
Interventions: THR-184, Placebo; Drug
Lead sponsor: Thrasos Innovation, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 26 more

Conditions: Program Evaluation, Child Sexual Abuse, Perpetration of Child Sexual Abuse, Prevention Intervention
Interventions: Help Wanted Prevention Intervention, Waitlist Control; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glomerulosclerosis, Focal
Interventions: Cyclosporin, MMF and Dexamethasone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 40 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Immune Modulation by Enhanced vs Standard Prehabilitation Program Before Major Surgery

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Optima: Optimizing Prograf Therapy in Maintenance Allografts II

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

Cyclosporine Vs Steroids in DRESS

Evaluation of HRP Among Pre-K Through 5th Grade

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

Genomics of Kidney Transplantation

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization

Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

Help Wanted: Evaluating a Prevention Intervention for People With Sexual Interest in Children

Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)